Femasys Inc (FEMY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Femasys Inc (FEMY) has a cash flow conversion efficiency ratio of -0.713x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.19 Million) by net assets ($5.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Femasys Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Femasys Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Femasys Inc for a breakdown of total debt and financial obligations.
Femasys Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Femasys Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hua Yang Bhd
KLSE:5062
|
-0.100x |
|
Peruvian Metals Corp
V:PER
|
-0.001x |
|
SIAV S.P.A.
F:F4U
|
N/A |
|
Alcom Group Bhd
KLSE:2674
|
0.069x |
|
Alla Public Company Limited
BK:ALLA
|
0.049x |
|
Klaria Pharma Holding AB
ST:KLAR
|
0.706x |
|
Renrenle Commercial Group Co Ltd
SHE:002336
|
0.110x |
|
Arctic Gold Publ AB
ST:ARCT
|
-0.102x |
Annual Cash Flow Conversion Efficiency for Femasys Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Femasys Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see FEMY market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.87 Million | $-18.69 Million | -3.184x | +62.26% |
| 2024-12-31 | $2.30 Million | $-19.44 Million | -8.438x | -1272.75% |
| 2023-12-31 | $18.35 Million | $-11.28 Million | -0.615x | +12.70% |
| 2022-12-31 | $15.24 Million | $-10.73 Million | -0.704x | -133.77% |
| 2021-12-31 | $26.33 Million | $-7.93 Million | -0.301x | +78.46% |
| 2020-12-31 | $3.53 Million | $-4.93 Million | -1.398x | -676.44% |
| 2019-12-31 | $-45.37 Million | $-11.01 Million | 0.243x | -- |
About Femasys Inc
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornua… Read more